Protocol to Obtain Blood Samples for Leukemia Research

This study is currently recruiting participants.
Verified February 2013 by Dartmouth-Hitchcock Medical Center
Sponsor:
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier:
NCT00889031
First received: April 24, 2009
Last updated: February 13, 2013
Last verified: February 2013

April 24, 2009
February 13, 2013
April 2009
April 2015   (final data collection date for primary outcome measure)
To determine the frequency with which CLL cells incubated ex vivo with vincristine undergo rapid interphase apoptosis. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00889031 on ClinicalTrials.gov Archive Site
To determine whether suppression or inhibition of BCL2 family members can acutely sensitize CLL cells to vincristine. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Protocol to Obtain Blood Samples for Leukemia Research
Protocol to Obtain Blood Samples for Leukemia Research

The purpose of this study is to collect a blood sample in patients with Chronic Lymphocytic Leukemia (CLL).

The blood sample will be used in the laboratory to perform studies focusing on Chronic Lymphocytic Leukemia (CLL).

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

10cc of peripheral blood.

Non-Probability Sample

Patients at Dartmouth-Hitchcock Medical Center's Norris Cotton Cancer Center

Chronic Lymphocytic Leukemia
Other: No Intervention
Patients with Chronic Lymphocytic Leukemia (CLL)
Other Name: No Intervention
No Treatment
Intervention: Other: No Intervention

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
April 2015
April 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients undergoing routine blood draws as part of their ongoing follow-up for Chronic Lymphocytic Leukemia (CLL) at the Norris Cotton Cancer Center of DHMC.

Exclusion Criteria:

  • Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for CLL or other disease process within the past 6 months are excluded. Use of intravenous immunoglobulin (IVIg) is not a reason for exclusion.
Both
18 Years and older
No
Contact: Research Nurse 800-639-6918 cancer.research.nurse@dartmouth.edu
Contact: Nancy Rollings 603-650-5135 Nancy.J.Rollings@Hitchcock.org
United States
 
NCT00889031
D0905
Yes
Dartmouth-Hitchcock Medical Center
Dartmouth-Hitchcock Medical Center
Not Provided
Principal Investigator: Christopher H Lowrey, MD Dartmouth-Hitchcock Medical Center
Dartmouth-Hitchcock Medical Center
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP